Helicobacter pylori may be an initiating factor in newly diagnosed ulcerative colitis patients: A pilot study

Table 1 Clinical manifestations of all participants in the study n (%)

Clinical manifestations	Ulcerative colitis (n = 30)	Control (n = 30)	P value
Abdominal pain	26 (86.6)	20 (66.6)	0.120
Bloody diarrhea	24 (80)	0 (0)	< 0.001a
Chronic non bloody diarrhea	6 (20)	22 (73.3)	< 0.001a
Fatigue	16 (53.3)	5 (16.6)	0.006a
Tenesmus	20 (66.6)	5 (16.6)	< 0.001a
Bleeding per rectum	0 (0)	8 (26.6)	0.007a
Constipation	0 (0)	4 (13.3)	0.120
Rectal pain	2 (6)	5 (16.6)	0.420
Anemia	24 (80)	9 (30)	0.001a

^aP value of < 0.05 is considered statistically significant.

Table 2 Laboratory investigations of the studied groups

		Ulcerative colitis (n = 30) mean ± SD	Control (n = 30) mean ± SD	P value
CBC	HB g/dL	9.52 ± 3.44	11.42 ± 2.02	0.010a
	Platelets 10³/mL	140.62 ± 83.91	195.7 ± 87.23	0.004a
	WBC cells/mL	8.65 ± 4.25	4.35 ± 2.58	< 0.001a
Liver functions	Bilirubin mg/dL	0.84 ± 0.41	0.75 ± 0.38	0.380
	Albumin g/dL	3.24 ± 1.42	3.82 ± 1.31	0.100
	AST IU/L	26.01 ± 12.00	21.1 ± 10.1	0.090
ESR	1st h	37.20 ± 18.10	15.03 ± 7.41	< 0.001a
	2nd h	46.12 ± 19.32	23.41 ± 9.13	< 0.001a

^aP value of < 0.05 is considered statistically significant. ESR: Erythrocyte sedimentation rate; WBC: White blood cell; AST: Aspartate transaminase.

Table 3 Comparison between Giemsa stain and Immunohistochemical stain in detection of Helicobacter pylori in all patients

Detection of H. pylori
Ulcerative colitis		Control
Giemsa stain	Immunohistochemical stain	Giemsa stain	Immunohistochemical stain
12/30 (40%)	17/30 (56.6%)	4/30 (13.3%)	6/30 (20%)
P = 0.30		P = 0.72

H. pylori:Helicobacter pylori.

Table 4 Comparison between ulcerative colitis patients and controls regarding presence of Helicobacter pylori as detected by Giemsa and immunohistochemical staining

Detection of H. pylori
Giemsa stain		Immunohistochemical stain
Ulcerative colitis	Control group	Ulcerative colitis	Control group
12/30 (40%)	4/30 (13.3%)	17/30 (56.6%)	6/30 (20%)
P = 0.04a		P = 0.007a

^aP value of < 0.05 is considered statistically significant. H. pylori: Helicobacter pylori.

Table 5 Histopathological diagnosis in relation to Helicobacter pylori staining in control group patients

Histopathological diagnosis	Giemsa stain		Immunohistochemical stain
	H. pylori positive (n = 4)	H. pylori negative (n = 26)	H. pylori positive (n = 6)	H. pylori negative (n = 24)
Normal	0	14	0	14
14/30 (46.67%)
Chronic nonspecific colitis	1	10	2	7
11/30 (36.66%)
Early microscopic features of UC	3	2	4	3
5/30 (16.66%)

H. pylori: Helicobacter pylori; UC: Ulcerative colitis.

Table 6 Erythrocyte sedimentation rate, C reactive protein, number of motions per day in the Helicobacter pylori treated and placebo group at baseline and after 2 wk of treatment

	H. pylori treated (n = 9)			Placebo (n = 8)
Parameters	Baseline	After 2 wk	P-value	Baseline	After 2 wk	P-value
ESR (1st)	38.56 ± 9.81	22.33 ± 5.55	< 0.001	37.50 ± 7.82	32.75 ± 6.34	0.203
ESR (2nd)	64 (54.25-73.25)	32 (30.5-37.5)	< 0.001	65.63 ± 11.51	58.75 ± 9.33	0.211
CRP	24 (22.5-36)	12 (6-12)	0.001	25.75 ± 9.29	24.12 ± 9.68	0.737
No. of motions per day	8 (6.75-9)	3 (2-3.25)	< 0.001	7.63 ± 1.41	6.88 ± 1.64	0.343

Data are presented as median (interquartile range) or mean and standard deviation. CRP: C reactive protein; ESR: Erythrocyte sedimentation rate.